Halla Nimeiri

3.4k total citations · 1 hit paper
84 papers, 1.8k citations indexed

About

Halla Nimeiri is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Halla Nimeiri has authored 84 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 25 papers in Cancer Research and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Halla Nimeiri's work include Cancer Genomics and Diagnostics (24 papers), Colorectal Cancer Treatments and Studies (24 papers) and Hepatocellular Carcinoma Treatment and Prognosis (14 papers). Halla Nimeiri is often cited by papers focused on Cancer Genomics and Diagnostics (24 papers), Colorectal Cancer Treatments and Studies (24 papers) and Hepatocellular Carcinoma Treatment and Prognosis (14 papers). Halla Nimeiri collaborates with scholars based in United States, Italy and Japan. Halla Nimeiri's co-authors include Al B. Benson, Sheetal Kircher, Mary F. Mulcahy, Aparna Kalyan, Paul J. Catalano, Peter J. O’Dwyer, George A. Fisher, Mark M. Zalupski, Teri A. Longacre and Diane Reidy‐Lagunes and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Halla Nimeiri

77 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

2022 125 citations Pamela L. Kunz, Noah Graham et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Halla Nimeiri United States	26	1.2k	446	386	349	318	84	1.8k
Lorenzo Antonuzzo Italy	23	1.3k 1.1×	404 0.9×	609 1.6×	264 0.8×	253 0.8×	173	1.9k
Rodney E. Wegner United States	24	782 0.7×	457 1.0×	907 2.3×	545 1.6×	198 0.6×	174	2.2k
Kevin Norwood United States	22	1.3k 1.1×	219 0.5×	504 1.3×	779 2.2×	97 0.3×	38	1.8k
Richard Quek Singapore	22	735 0.6×	211 0.5×	591 1.5×	198 0.6×	94 0.3×	64	1.5k
Vera Gorbounova Russia	13	2.2k 1.9×	407 0.9×	1.8k 4.8×	280 0.8×	279 0.9×	23	3.2k
Sarah Taylor United States	17	998 0.9×	251 0.6×	681 1.8×	316 0.9×	64 0.2×	38	1.9k
Olivier Dubreuil France	15	932 0.8×	159 0.4×	498 1.3×	378 1.1×	56 0.2×	56	1.6k
E. Samantas Greece	21	1.5k 1.3×	542 1.2×	618 1.6×	224 0.6×	37 0.1×	68	1.9k
Antoine Adenis France	24	698 0.6×	128 0.3×	1.1k 2.8×	500 1.4×	269 0.8×	84	2.0k
L H Einhorn United States	21	1.5k 1.2×	314 0.7×	1.3k 3.3×	875 2.5×	163 0.5×	31	2.7k

Countries citing papers authored by Halla Nimeiri

Since Specialization

Citations

This map shows the geographic impact of Halla Nimeiri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Halla Nimeiri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Halla Nimeiri more than expected).

Fields of papers citing papers by Halla Nimeiri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Halla Nimeiri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Halla Nimeiri. The network helps show where Halla Nimeiri may publish in the future.

Co-authorship network of co-authors of Halla Nimeiri

This figure shows the co-authorship network connecting the top 25 collaborators of Halla Nimeiri. A scholar is included among the top collaborators of Halla Nimeiri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Halla Nimeiri. Halla Nimeiri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ben‐Shachar, Rotem, Josephine Feliciano, Kyle A. Beauchamp, et al.. (2024). Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open. 7(11). e2442970–e2442970. 5 indexed citations

Nakamura, Yoshiaki, Kristiyana Kaneva, Christine Lo, et al.. (2024). Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in patients with resected stage II and III colorectal cancer: A subset analysis from the GALAXY study in CIRCULATE-Japan.. Journal of Clinical Oncology. 42(16_suppl). 3618–3618. 2 indexed citations

Iams, Wade T., Matthew MacKay, Rotem Ben‐Shachar, et al.. (2024). Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort. JAMA Network Open. 7(1). e2351700–e2351700. 31 indexed citations

Driessen, Terri M., Christine Lo, Wei Zhu, et al.. (2024). Abstract 3498: A novel combination of tissue-informed, comprehensive genomic profiling (CGP) and non-bespoke blood-based profiling for quantifying circulating tumor DNA (ctDNA). Cancer Research. 84(6_Supplement). 3498–3498.

Stein, Michelle M., Paul Fields, Luca Lonini, et al.. (2023). 163 A multi-modal, pan-cancer atlas of tumor-immune states across primary and metastatic disease using a large, real-world database. SHILAP Revista de lepidopterología. A182–A184.

Aggarwal, Charu, Yinjie Gao, Seung Won Hyun, et al.. (2023). Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy. JAMA Network Open. 6(5). e2311181–e2311181. 69 indexed citations

Mulcahy, Mary F., Halla Nimeiri, Osama E. Rahma, et al.. (2023). Real-world outcome analysis of patients with advanced gastric and gastroesophageal adenocarcinoma with HER2-low expression treated with first-line therapy.. Journal of Clinical Oncology. 41(4_suppl). 326–326. 2 indexed citations

Patel, Jyoti D., Rotem Ben‐Shachar, Matthew J. Carty, et al.. (2023). 185P Real-world data analysis of genomic profiling-matched targeted therapy outcomes in patients with fusion-positive NSCLC. Annals of Oncology. 34. S255–S255. 1 indexed citations

Kennecke, Hagen F., Chris J. O’Callaghan, Jonathan M. Loree, et al.. (2022). Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results. Journal of Clinical Oncology. 41(2). 233–242. 31 indexed citations

10.

Graf, Ryon P., Virginia Fisher, James Creeden, et al.. (2022). Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer. Cancer Research Communications. 2(9). 1037–1048. 7 indexed citations

11.

Kunz, Pamela L., Noah Graham, Paul J. Catalano, et al.. (2022). Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). Journal of Clinical Oncology. 41(7). 1359–1369. 125 indexed citations breakdown →

12.

Cannon, Timothy Lewis, Ethan S. Sokol, Raymond Wadlow, et al.. (2022). Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS. Cancer Treatment and Research Communications. 32. 100569–100569. 4 indexed citations

13.

Hickey, Ryan, Laura Kulik, Halla Nimeiri, et al.. (2017). Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. Journal of Vascular and Interventional Radiology. 28(11). 1487–1494. 27 indexed citations

14.

Nimeiri, Halla, et al.. (2016). Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?. Current Treatment Options in Oncology. 17(6). 26–26. 11 indexed citations

15.

Kircher, Sheetal, Halla Nimeiri, & Al B. Benson. (2016). Targeting Angiogenesis in Colorectal Cancer. The Cancer Journal. 22(3). 182–189. 27 indexed citations

16.

Reddy, Sangeetha M., Maxwell T. Vergo, Judith A. Paice, et al.. (2015). Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies. Clinical Colorectal Cancer. 15(1). 37–46. 29 indexed citations

17.

Kalyan, Aparna, Halla Nimeiri, & Laura Kulik. (2015). Systemic Therapy of Hepatocellular Carcinoma. Clinics in Liver Disease. 19(2). 421–432. 35 indexed citations

18.

Nimeiri, Halla, et al.. (2014). A feasibility study of dignity therapy in patients with stage IV colorectal cancer actively receiving second-line chemotherapy. The Journal of Community and Supportive Oncology. 12(12). 446–453. 24 indexed citations

19.

Landry, Jerome C., Yang Feng, Steven J. Cohen, et al.. (2013). Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5‐fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Cancer. 119(8). 1521–1527. 41 indexed citations

20.

Nimeiri, Halla, Amit M. Oza, Robert J. Morgan, et al.. (2010). A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecologic Oncology. 117(1). 37–40. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact